214 related articles for article (PubMed ID: 1672375)
21. Hypotensive and bradycardic effects elicited by spinal dopamine receptor stimulation: effects of D1 and D2 receptor agonists and antagonists.
Pellissier G; Demenge P
J Cardiovasc Pharmacol; 1991 Oct; 18(4):548-55. PubMed ID: 1724532
[TBL] [Abstract][Full Text] [Related]
22. Identification of fenoldopam prodrugs with prolonged renal vasodilator activity.
Brooks DP; DePalma PD; Cyronak MJ; Bryant MA; Karpinski K; Mico B; Gaitanopoulos DE; Chambers PA; Erhard KF; Weinstock J
J Pharmacol Exp Ther; 1990 Sep; 254(3):1084-9. PubMed ID: 1975620
[TBL] [Abstract][Full Text] [Related]
23. Studies on vascular dopamine receptors with the dopamine receptor agonist: SK&F 82526.
Ohlstein EH; Zabko-Potapovich B; Berkowitz BA
J Pharmacol Exp Ther; 1984 May; 229(2):433-9. PubMed ID: 6143817
[TBL] [Abstract][Full Text] [Related]
24. Different dopamine receptor subtypes mediate the neurogenic vasodilation produced by fenoldopam and SK & F 85174 in the dog hindlimb.
Lokhandwala MF; Watkins HO; Dlewati A
Eur J Pharmacol; 1987 Nov; 143(3):383-90. PubMed ID: 2891555
[TBL] [Abstract][Full Text] [Related]
25. Functional and biochemical evidence for the lack of cardiac presynaptic alpha-2 adrenoceptor stimulant properties of cirazoline (LD 3098), a potent alpha-1 adrenoceptor agonist in dogs and rats.
Cavero I; Lefèvre-Borg F; Roach AG; Gomeni R; Scatton B
J Pharmacol Exp Ther; 1982 Oct; 223(1):241-50. PubMed ID: 6126583
[TBL] [Abstract][Full Text] [Related]
26. Cardiovascular responses in healthy subjects to a novel oral dopamine agonist, fenoldopam.
Cregeen RJ; Rudge PJ; Mills JG; Vincent SH; Burland WL
J Hypertens Suppl; 1985 Dec; 3(3):S173-5. PubMed ID: 2908814
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the effects of the novel inotropic agent, ibopamine, with epinine, dopamine and fenoldopam on renal vascular dopamine receptors in the anesthetized dog.
Nichols AJ; Smith JM; Shebuski RJ; Ruffolo RR
J Pharmacol Exp Ther; 1987 Aug; 242(2):573-8. PubMed ID: 2886644
[TBL] [Abstract][Full Text] [Related]
28. Systemic and pulmonary vascular effects of selective dopamine receptor blockade and stimulation in lambs.
Polak MJ; Drummond WH
Pediatr Res; 1993 Feb; 33(2):181-4. PubMed ID: 8094550
[TBL] [Abstract][Full Text] [Related]
29. Dopamine1 receptor agonist and alpha-2 adrenoceptor antagonist effects of fenoldopam in rabbits.
Szabo B; Hedler L; Starke K
J Pharmacol Exp Ther; 1986 Dec; 239(3):881-6. PubMed ID: 2879034
[TBL] [Abstract][Full Text] [Related]
30. Antagonism of a specific dopaminergic receptor agonist with metoclopramide in horses.
Eades SC; Moore JN
Am J Vet Res; 1993 Jan; 54(1):122-5. PubMed ID: 8093992
[TBL] [Abstract][Full Text] [Related]
31. Evidence against a role for dopamine D1 receptors in the myocardium of the pig.
Van Woerkens LJ; Duncker DJ; Den Boer MO; McFalls EO; Sassen LM; Saxena PR; Verdouw PD
Br J Pharmacol; 1991 Sep; 104(1):246-50. PubMed ID: 1686206
[TBL] [Abstract][Full Text] [Related]
32. Locomotor activity following intra-accumbens microinjections of dopamine D1 agonist SK&F 38393 in rats.
Meyer ME; Van Hartesveldt C; Potter TJ
Synapse; 1993 Apr; 13(4):310-4. PubMed ID: 8097596
[TBL] [Abstract][Full Text] [Related]
33. Analysis of the effects of dopamine-1 and dopamine-2 receptor agonists on coronary flow.
Zhao RR; Wang PH; Zhang WF; Fennell WH
Methods Find Exp Clin Pharmacol; 1992; 14(1):5-11. PubMed ID: 1352371
[TBL] [Abstract][Full Text] [Related]
34. Hypotensive and regional hemodynamic effects of the dopamine receptor agonist SK & F 85174 in the anesthetized rat.
Van der Niepen P; Schoors DF; Dupont AG
Arch Int Pharmacodyn Ther; 1991; 313():98-107. PubMed ID: 1687774
[TBL] [Abstract][Full Text] [Related]
35. Activation of DA1 receptors by dopamine or fenoldopam increases cyclic AMP levels in the renal artery but not in the superior cervical ganglion of the rat.
Alkadhi KA; Sabouni MH; Ansari AF; Lokhandwala MF
J Pharmacol Exp Ther; 1986 Aug; 238(2):547-53. PubMed ID: 2874213
[TBL] [Abstract][Full Text] [Related]
36. Effects of alpha adrenoceptor and dopamine receptor agonists and antagonists on ganglionic transmission.
Satoh Y; Kohli JD; Goldberg LI
J Pharmacol Exp Ther; 1989 Oct; 251(1):253-7. PubMed ID: 2571718
[TBL] [Abstract][Full Text] [Related]
37. Topographical resolution of jaw movements mediated by cyclase- vs. non-cyclase-coupled dopamine D(1)-like receptors: studies with SK&F 83822.
Fujita S; Lee J; Kiguchi M; Uchida T; Cools AR; Waddington JL; Koshikawa N
Eur J Pharmacol; 2006 May; 538(1-3):94-100. PubMed ID: 16682023
[TBL] [Abstract][Full Text] [Related]
38. Pharmacology of SK&F R-105058 and R-106114, N-ethyl carbamate ester prodrugs of fenoldopam.
Brooks DP; DePalma PD; Cyronak MJ; Karpinski K; Weinstock J
Pharmacology; 1990; 41(5):299-308. PubMed ID: 1982634
[TBL] [Abstract][Full Text] [Related]
39. Urethane inhibits cardiovascular responses mediated by the stimulation of alpha-2 adrenoceptors in the rat.
Armstrong JM; Lefèvre-Borg F; Scatton B; Cavero I
J Pharmacol Exp Ther; 1982 Nov; 223(2):524-35. PubMed ID: 6127404
[TBL] [Abstract][Full Text] [Related]
40. Demonstration of specific dopamine-1 receptor-mediated coronary vasodilation in the anesthetized dog.
Kopia GA; Valocik RE
J Pharmacol Exp Ther; 1989 Jan; 248(1):215-21. PubMed ID: 2563287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
